Vor Bio announced on September 17, 2025, that 48-week clinical data from the Phase 3 study in China evaluating telitacicept in adults with generalized myasthenia gravis (gMG) will be presented as an oral presentation. This presentation is scheduled for the American Association of Neuromuscular & Electrodiagnostic Medicine (AANEM) Annual Meeting, taking place from October 29 to November 1, 2025.
The study, sponsored by Vor Bio's collaborator RemeGen Co., Ltd, previously demonstrated a placebo-adjusted 4.83-point improvement in the Myasthenia Gravis Activities of Daily Living (MG-ADL) scale at 24 weeks, which was the primary endpoint of the trial. The upcoming 48-week data will provide more mature and comprehensive insights into telitacicept's efficacy and safety profile.
The oral presentation, titled "Efficacy and Safety of Telitacicept in Patients with Generalized Myasthenia Gravis: Results from a Phase 3 Study," is a significant event for Vor Bio. It will highlight the potential of telitacicept, a novel dual-target fusion protein, to address the unmet clinical needs of patients with gMG globally, further solidifying the company's strategic focus on autoimmune diseases.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.